Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 18/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 18/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 18/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 1.00 |
| ▸ | VNN1 | O95497 | 2/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18742382 | 0.90 | HDAC6 (0.82) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL19267849 | 0.89 | HDAC3 (0.80) | HDAC3HDAC1HDAC2HDAC6HDAC4 | |
| SCHEMBL4732185 | 0.88 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18742655 | 0.87 | HDAC6 (0.77) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL4730029 | 0.86 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6HDAC4 | |
| SCHEMBL18742577 | 0.86 | HDAC3 (0.75) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL18742630 | 0.85 | HDAC6 (0.74) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| SCHEMBL4729535 | 0.85 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6HDAC4 | |
| SCHEMBL4729867 | 0.84 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6HDAC4 | |
| SCHEMBL4732526 | 0.83 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210155593-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | REGENACY PHARMACEUTICALS LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10858323-B2 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | REGENACY PHARMACEUTICALS, LLC (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190106392-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | ACETYLON PHARMACEUTICALS, INC. | 2019-04-11 | — | — | US | disclosed |
| US-10040769-B2 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | REGENACY PHARMACEUTICALS, LLC (US) | 2018-08-07 | — | — | US | disclosed |
| WO-2017075192-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | ACETYLON PHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| US-20170114023-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | ACETYLON PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170096403-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS, INC. | 2017-04-06 | — | — | US | disclosed |
| EP-3067346-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | Acetylon Pharmaceuticals, Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9409890-B2 | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARAMCEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160158231-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS FOR TREATING PERIPHERAL NEUROPATHY | REGENACY PHARMACEUTICALS, LLC | 2016-06-09 | — | — | US | disclosed |
| EP-2640709-B1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS INC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20150359794-A1 | IMPAIRMENT OF THE LARGE RIBOSOMAL SUBUNIT PROTEIN RPL24 BY DEPLETION OR ACETYLATION | BUCK INSTITUTE FOR RESEARCH ON AGING | 2015-12-17 | — | — | US | disclosed |
| US-20150359794-A1 | IMPAIRMENT OF THE LARGE RIBOSOMAL SUBUNIT PROTEIN RPL24 BY DEPLETION OR ACETYLATION | BUCK INSTITUTE FOR RESEARCH ON AGING | 2015-12-17 | — | — | US | disclosed |
| US-20140142104-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS, INC. | 2014-05-22 | — | — | US | disclosed |
| WO-2012068109-A2 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120121502-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155593-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | HDAC4, HDAC5, HDAC9 | HDAC3 7/4885HDAC1 4/4885HDAC2 5/4885 |
| US-20140142104-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC5 | HDAC3 8/4885HDAC1 2/4885HDAC2 5/4885 |
| US-20160158231-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS FOR TREATING PERIPHERAL NEUROPATHY | HDAC5, HDAC4, HDAC9 | HDAC3 8/4885HDAC1 6/4885HDAC2 5/4885 |
| US-20170114023-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | HDAC4, HDAC5, HDAC9 | HDAC3 7/4885HDAC1 4/4885HDAC2 5/4885 |
| US-10040769-B2 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | HDAC4, HDAC5, HDAC9 | HDAC3 7/4885HDAC1 4/4885HDAC2 5/4885 |
| US-20190106392-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | HDAC4, HDAC5, HDAC9 | HDAC3 7/4885HDAC1 4/4885HDAC2 5/4885 |
| US-10858323-B2 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | HDAC4, HDAC5, HDAC9 | HDAC3 7/4885HDAC1 4/4885HDAC2 5/4885 |
| US-20120121502-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC5 | HDAC3 8/4885HDAC1 2/4885HDAC2 5/4885 |
| US-20150359794-A1 | IMPAIRMENT OF THE LARGE RIBOSOMAL SUBUNIT PROTEIN RPL24 BY DEPLETION OR ACETYLATION | RPL24, RPS24, RPL26 | HDAC3 44/4885HDAC1 7/4885HDAC2 34/4885 |
| US-20170096403-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC5 | HDAC3 8/4885HDAC1 2/4885HDAC2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.